This is a multi-center, randomized, double-blind, placebo-controlled, inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117570 in adults with a primary diagnosis of schizophrenia who are experiencing a worsening or relapse of symptoms.
The goal of the study is to see how well NBI-1117570 works, how safe it is, and how well it is tolerated compared to the placebo. Participants in this study have a 50:50 chance of receiving NBI-1117570 or placebo and will be randomly assigned to take 1 study medicine or the other. The expected duration of study participation for each participant is approximately 9 weeks.
